Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
4
×
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
4
×
san francisco blog main
4
×
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
indiana blog main
indiana top stories
intercept pharmaceuticals
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
celgene
clinical trials
liver
nash
nonalcoholic steatohepatitis
obeticholic acid
2019
4d molecular therapeutics
abbvie
acne
activism
What
disease
4
×
drug
4
×
liver
approved
bio
fatty
known
medicine
nash
race
roundup
advanced
alnylam’s
alzheimer's
approval
bad
bff
brain
cancer
case
companies
conference
data
deals
devoted
digital
doses
easl
epidemic
failed
fda
fight
form
fortune
frenzied
gene
goes
growing
help
horizon
Language
Current search:
disease
×
drug
×
" national blog main "
×
" san diego top stories "
×
" san francisco blog main "
×
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug